Cargando…
A BCMA-specific CAR T cell produced with clinically scalable lentiviral and T cell manufacturing processes has potent anti-multiple myeloma activity
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645500/ http://dx.doi.org/10.1186/2051-1426-3-S2-P124 |
| _version_ | 1782400826635976704 |
|---|---|
| author | Garrett, Tracy E Chekmasova, Alena A Evans, John W Seidel, Stacie L Horton, Holly M Latimer, Howard J Griecci, Johanna A Horvath, Christopher J Ryu, Byoung Y Friedman, Kevin M Morgan, Richard A |
| author_facet | Garrett, Tracy E Chekmasova, Alena A Evans, John W Seidel, Stacie L Horton, Holly M Latimer, Howard J Griecci, Johanna A Horvath, Christopher J Ryu, Byoung Y Friedman, Kevin M Morgan, Richard A |
| author_sort | Garrett, Tracy E |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4645500 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2015 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-46455002015-11-20 A BCMA-specific CAR T cell produced with clinically scalable lentiviral and T cell manufacturing processes has potent anti-multiple myeloma activity Garrett, Tracy E Chekmasova, Alena A Evans, John W Seidel, Stacie L Horton, Holly M Latimer, Howard J Griecci, Johanna A Horvath, Christopher J Ryu, Byoung Y Friedman, Kevin M Morgan, Richard A J Immunother Cancer Poster Presentation BioMed Central 2015-11-04 /pmc/articles/PMC4645500/ http://dx.doi.org/10.1186/2051-1426-3-S2-P124 Text en Copyright © 2015 Garrett et al. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| spellingShingle | Poster Presentation Garrett, Tracy E Chekmasova, Alena A Evans, John W Seidel, Stacie L Horton, Holly M Latimer, Howard J Griecci, Johanna A Horvath, Christopher J Ryu, Byoung Y Friedman, Kevin M Morgan, Richard A A BCMA-specific CAR T cell produced with clinically scalable lentiviral and T cell manufacturing processes has potent anti-multiple myeloma activity |
| title | A BCMA-specific CAR T cell produced with clinically scalable lentiviral and T cell manufacturing processes has potent anti-multiple myeloma activity |
| title_full | A BCMA-specific CAR T cell produced with clinically scalable lentiviral and T cell manufacturing processes has potent anti-multiple myeloma activity |
| title_fullStr | A BCMA-specific CAR T cell produced with clinically scalable lentiviral and T cell manufacturing processes has potent anti-multiple myeloma activity |
| title_full_unstemmed | A BCMA-specific CAR T cell produced with clinically scalable lentiviral and T cell manufacturing processes has potent anti-multiple myeloma activity |
| title_short | A BCMA-specific CAR T cell produced with clinically scalable lentiviral and T cell manufacturing processes has potent anti-multiple myeloma activity |
| title_sort | bcma-specific car t cell produced with clinically scalable lentiviral and t cell manufacturing processes has potent anti-multiple myeloma activity |
| topic | Poster Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645500/ http://dx.doi.org/10.1186/2051-1426-3-S2-P124 |
| work_keys_str_mv | AT garretttracye abcmaspecificcartcellproducedwithclinicallyscalablelentiviralandtcellmanufacturingprocesseshaspotentantimultiplemyelomaactivity AT chekmasovaalenaa abcmaspecificcartcellproducedwithclinicallyscalablelentiviralandtcellmanufacturingprocesseshaspotentantimultiplemyelomaactivity AT evansjohnw abcmaspecificcartcellproducedwithclinicallyscalablelentiviralandtcellmanufacturingprocesseshaspotentantimultiplemyelomaactivity AT seidelstaciel abcmaspecificcartcellproducedwithclinicallyscalablelentiviralandtcellmanufacturingprocesseshaspotentantimultiplemyelomaactivity AT hortonhollym abcmaspecificcartcellproducedwithclinicallyscalablelentiviralandtcellmanufacturingprocesseshaspotentantimultiplemyelomaactivity AT latimerhowardj abcmaspecificcartcellproducedwithclinicallyscalablelentiviralandtcellmanufacturingprocesseshaspotentantimultiplemyelomaactivity AT grieccijohannaa abcmaspecificcartcellproducedwithclinicallyscalablelentiviralandtcellmanufacturingprocesseshaspotentantimultiplemyelomaactivity AT horvathchristopherj abcmaspecificcartcellproducedwithclinicallyscalablelentiviralandtcellmanufacturingprocesseshaspotentantimultiplemyelomaactivity AT ryubyoungy abcmaspecificcartcellproducedwithclinicallyscalablelentiviralandtcellmanufacturingprocesseshaspotentantimultiplemyelomaactivity AT friedmankevinm abcmaspecificcartcellproducedwithclinicallyscalablelentiviralandtcellmanufacturingprocesseshaspotentantimultiplemyelomaactivity AT morganricharda abcmaspecificcartcellproducedwithclinicallyscalablelentiviralandtcellmanufacturingprocesseshaspotentantimultiplemyelomaactivity AT garretttracye bcmaspecificcartcellproducedwithclinicallyscalablelentiviralandtcellmanufacturingprocesseshaspotentantimultiplemyelomaactivity AT chekmasovaalenaa bcmaspecificcartcellproducedwithclinicallyscalablelentiviralandtcellmanufacturingprocesseshaspotentantimultiplemyelomaactivity AT evansjohnw bcmaspecificcartcellproducedwithclinicallyscalablelentiviralandtcellmanufacturingprocesseshaspotentantimultiplemyelomaactivity AT seidelstaciel bcmaspecificcartcellproducedwithclinicallyscalablelentiviralandtcellmanufacturingprocesseshaspotentantimultiplemyelomaactivity AT hortonhollym bcmaspecificcartcellproducedwithclinicallyscalablelentiviralandtcellmanufacturingprocesseshaspotentantimultiplemyelomaactivity AT latimerhowardj bcmaspecificcartcellproducedwithclinicallyscalablelentiviralandtcellmanufacturingprocesseshaspotentantimultiplemyelomaactivity AT grieccijohannaa bcmaspecificcartcellproducedwithclinicallyscalablelentiviralandtcellmanufacturingprocesseshaspotentantimultiplemyelomaactivity AT horvathchristopherj bcmaspecificcartcellproducedwithclinicallyscalablelentiviralandtcellmanufacturingprocesseshaspotentantimultiplemyelomaactivity AT ryubyoungy bcmaspecificcartcellproducedwithclinicallyscalablelentiviralandtcellmanufacturingprocesseshaspotentantimultiplemyelomaactivity AT friedmankevinm bcmaspecificcartcellproducedwithclinicallyscalablelentiviralandtcellmanufacturingprocesseshaspotentantimultiplemyelomaactivity AT morganricharda bcmaspecificcartcellproducedwithclinicallyscalablelentiviralandtcellmanufacturingprocesseshaspotentantimultiplemyelomaactivity |